LONDON, U.K. — The pharmaceutical industry is facing unprecedented challenges on many fronts – a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.

NEW YORK, N.Y. and LONDON, U.K. (SEND2PRESS NEWSWIRE) — Eularis is announcing the release of its report ‘How To Harness The Power Of Social Media In Pharmaceutical eMarketing.’ This report puts to rest the issues around ‘can’t,’ and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives.

NEW YORK, N.Y., and LONDON, U.K., May 18 (SEND2PRESS NEWSWIRE) — Eularis is announcing the release of an update to its report ‘Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web 2.0 and Beyond.’ The comprehensive report has been created to demystify the world of eMarketing and Social Media to provide Pharmaceutical marketers with a competitive edge and the latest information on how to use these emerging tools.

LONDON, U.K., May 18 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you are making the wrong marketing decision. The Pharmaceutical Industry is under significant pressure to consider its costs very carefully. Since marketing budgets often represent a major portion of a company’s cost base, they can easily become the target of budget cuts. The pressure to measure marketing return and effectiveness has never been stronger.

NEW YORK, LONDON, TOKYO, Nov. 17 (SEND2PRESS NEWSWIRE) — In today’s environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and profits – until recently. Every Pharma company today is hoping to achieve their own immediate winners, the drugs that are successful right from the start and provide years of business-sustaining profit. However, recent studies have shown that seven out of ten drugs launched in the last five years have failed to repay their R&D investment.

NEW YORK, N.Y. and LONDON, U.K., Sept. 16 (SEND2PRESS NEWSWIRE) — Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, ‘Implementing a pre-launch named patient programme – evidence of increased market share,’ provides pharmaceutical companies with insight and mathematical justification into the cash market share and revenue impact of pre-launch NPPs on brands, while outlining the benefits and challenges that they create.

TOKYO and LONDON, U.K., May 12 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan.

NEW YORK, N.Y. and LONDON, U.K., April 21 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return, at 3rd Annual Pharmaceutical Market Research Summit.

NEW YORK, N.Y. and LONDON, U.K., March 12 (SEND2PRESS NEWSWIRE) — Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, ‘Ensuring Profitable Patient Adherence Programs.’

NEW YORK, N.Y. and LONDON, U.K., March 10 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry.

LONDON, U.K. and NEW YORK, N.Y. – Nov. 20 (SEND2PRESS NEWSWIRE) — With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years.